644 related articles for article (PubMed ID: 2574005)
1. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
Fisher LM; Lawrence JM; Josty IC; Hopewell R; Margerrison EE; Cullen ME
Am J Med; 1989 Nov; 87(5A):2S-8S. PubMed ID: 2574005
[TBL] [Abstract][Full Text] [Related]
2. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
[TBL] [Abstract][Full Text] [Related]
3. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
4. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
Ng EY; Trucksis M; Hooper DC
Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the mutations involved in fluoroquinolone resistance of in vivo and in vitro mutants of Escherichia coli.
Bachoual R; Tankovic J; Soussy CJ
Microb Drug Resist; 1998; 4(4):271-6. PubMed ID: 9988045
[TBL] [Abstract][Full Text] [Related]
6. Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones.
Cullen ME; Wyke AW; Kuroda R; Fisher LM
Antimicrob Agents Chemother; 1989 Jun; 33(6):886-94. PubMed ID: 2548439
[TBL] [Abstract][Full Text] [Related]
7. A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors.
Hsiung Y; Elsea SH; Osheroff N; Nitiss JL
J Biol Chem; 1995 Sep; 270(35):20359-64. PubMed ID: 7657608
[TBL] [Abstract][Full Text] [Related]
8. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
Strahilevitz J; Robicsek A; Hooper DC
Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
[TBL] [Abstract][Full Text] [Related]
9. Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae.
Roychoudhury S; Twinem TL; Makin KM; McIntosh EJ; Ledoussal B; Catrenich CE
J Antimicrob Chemother; 2001 Jul; 48(1):29-36. PubMed ID: 11418510
[TBL] [Abstract][Full Text] [Related]
10. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
[TBL] [Abstract][Full Text] [Related]
11. Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.
Chen JY; Siu LK; Chen YH; Lu PL; Ho M; Peng CF
Microb Drug Resist; 2001; 7(1):47-53. PubMed ID: 11310803
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the mechanisms of quinolone resistance in clinical isolates of Citrobacter freundii.
Navia MM; Ruiz J; Ribera A; de Anta MT; Vila J
J Antimicrob Chemother; 1999 Dec; 44(6):743-8. PubMed ID: 10590274
[TBL] [Abstract][Full Text] [Related]
13. Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field.
Giraud E; Brisabois A; Martel JL; Chaslus-Dancla E
Antimicrob Agents Chemother; 1999 Sep; 43(9):2131-7. PubMed ID: 10471553
[TBL] [Abstract][Full Text] [Related]
14. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa.
Mouneimné H; Robert J; Jarlier V; Cambau E
Antimicrob Agents Chemother; 1999 Jan; 43(1):62-6. PubMed ID: 9869566
[TBL] [Abstract][Full Text] [Related]
15. Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates.
Kureishi A; Diver JM; Beckthold B; Schollaardt T; Bryan LE
Antimicrob Agents Chemother; 1994 Sep; 38(9):1944-52. PubMed ID: 7811002
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of quinolone resistance in Staphylococcus aureus.
Tanaka M; Wang T; Onodera Y; Uchida Y; Sato K
J Infect Chemother; 2000 Sep; 6(3):131-9. PubMed ID: 11810552
[TBL] [Abstract][Full Text] [Related]
17. Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections.
Ozeki S; Deguchi T; Yasuda M; Nakano M; Kawamura T; Nishino Y; Kawada Y
J Clin Microbiol; 1997 Sep; 35(9):2315-9. PubMed ID: 9276409
[TBL] [Abstract][Full Text] [Related]
18. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
Fournier B; Hooper DC
Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
[TBL] [Abstract][Full Text] [Related]
19. gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.
Oh H; El Amin N; Davies T; Appelbaum PC; Edlund C
Antimicrob Agents Chemother; 2001 Jul; 45(7):1977-81. PubMed ID: 11408211
[TBL] [Abstract][Full Text] [Related]
20. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
